Published in J Antibiot (Tokyo) on October 01, 2008
Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model. Antimicrob Agents Chemother (2011) 0.89
Vancomycin analogs: Seeking improved binding of d-Ala-d-Ala and d-Ala-d-Lac peptides by side-chain and backbone modifications. Bioorg Med Chem (2009) 0.86
Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic. Antimicrob Agents Chemother (2011) 0.83
Host-guest chemistry of the peptidoglycan. J Med Chem (2010) 0.82
In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species. Antimicrob Agents Chemother (2012) 0.76
TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother (2012) 0.76
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med (2003) 6.57
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2005) 4.22
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol (2005) 3.51
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother (2005) 2.72
In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother (2003) 2.60
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med (2008) 2.37
Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway. J Clin Invest (2007) 2.36
Remote ischemic preconditioning in human coronary artery bypass surgery: from promise to disappointment? Circulation (2010) 2.25
Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother (2004) 2.17
Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med (2008) 2.01
Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother (2004) 2.01
Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother (2013) 1.98
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother (2007) 1.93
A prospective, randomized study of preoperative autologous donation for hip replacement surgery. J Bone Joint Surg Am (2002) 1.83
Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans: the NHLBI Exome Sequencing Project. Blood (2013) 1.69
Platelet and coagulation defects associated with HIV-1-infection. Thromb Haemost (2002) 1.66
Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother (2007) 1.62
Exposure, health and ecological effects review of engineered nanoscale cerium and cerium oxide associated with its use as a fuel additive. Crit Rev Toxicol (2011) 1.52
Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation (2003) 1.51
Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother (2008) 1.43
Preventive effect of specific antioxidant on oxidative renal cell injury associated with renal crystal formation. Urology (2013) 1.41
Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo) (2004) 1.38
ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother (2009) 1.38
In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother (2008) 1.36
Predicting emergency department admissions. Emerg Med J (2011) 1.34
Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother (2010) 1.33
Will working memory training generalize to improve off-task behavior in children with attention-deficit/hyperactivity disorder? Neurotherapeutics (2012) 1.29
Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol (2003) 1.25
D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation (2003) 1.22
Optimised anaesthesia to reduce post operative cognitive decline (POCD) in older patients undergoing elective surgery, a randomised controlled trial. PLoS One (2012) 1.21
A central strategy for converting natural products into fluorescent probes. Chembiochem (2006) 1.21
Particulate matter-induced lung inflammation increases systemic levels of PAI-1 and activates coagulation through distinct mechanisms. PLoS One (2011) 1.21
Statin use and functional decline in patients with and without peripheral arterial disease. J Am Coll Cardiol (2006) 1.20
The osteo-odonto-keratoprosthesis (OOKP). Semin Ophthalmol (2005) 1.18
A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care (2012) 1.18
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin (2008) 1.18
Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2005) 1.17
D-dimer and inflammatory markers as predictors of functional decline in men and women with and without peripheral arterial disease. J Am Geriatr Soc (2005) 1.16
Semi-synthetic glycopeptide antibacterials. Bioorg Med Chem Lett (2003) 1.14
Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics than intermittent claudication. Circulation (2008) 1.12
Trophic effects of platelets on cultured endothelial cells are mediated by platelet-associated fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF). Thromb Haemost (2002) 1.12
Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother (2005) 1.12
In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models. Antimicrob Agents Chemother (2011) 1.11
Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother (2006) 1.10
Elevated levels of inflammation, d-dimer, and homocysteine are associated with adverse calf muscle characteristics and reduced calf strength in peripheral arterial disease. J Am Coll Cardiol (2007) 1.09
Controlled differentiation of human bone marrow stromal cells using magnetic nanoparticle technology. Tissue Eng Part A (2010) 1.08
Management of Clostridium difficile in NHS trusts. BMJ (2006) 1.07
Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost (2002) 1.03
Multivalent drug design. Synthesis and in vitro analysis of an array of vancomycin dimers. J Am Chem Soc (2003) 1.02
β₂-Adrenergic agonists augment air pollution-induced IL-6 release and thrombosis. J Clin Invest (2014) 1.00
Splenic peliosis and rupture in patients with dyskeratosis congenita on androgens and granulocyte colony-stimulating factor. Br J Haematol (2007) 1.00
Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate. Mol Cell Biol (2002) 1.00
Towards a synthetic osteo-odonto-keratoprosthesis. Acta Biomater (2008) 0.99
Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF. J Immunol Methods (2010) 0.99
In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci. Diagn Microbiol Infect Dis (2011) 0.98
Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. Antimicrob Agents Chemother (2010) 0.98
The impact of the congestion charging scheme on air quality in London. Part 1. Emissions modeling and analysis of air pollution measurements. Res Rep Health Eff Inst (2011) 0.96
Functional decline in patients with and without peripheral arterial disease: predictive value of annual changes in levels of C-reactive protein and D-dimer. J Gerontol A Biol Sci Med Sci (2006) 0.95
Inflammatory and thrombotic blood markers and walking-related disability in men and women with and without peripheral arterial disease. J Am Geriatr Soc (2004) 0.94
Transforming a Targeted Porphyrin Theranostic Agent into a PET Imaging Probe for Cancer. Theranostics (2011) 0.94
Circulating blood markers and functional impairment in peripheral arterial disease. J Am Geriatr Soc (2008) 0.94
Particulate matter oxidative potential from waste transfer station activity. Environ Health Perspect (2010) 0.94
In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother (2005) 0.92
Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. J Antimicrob Chemother (2010) 0.92
Inflammatory markers, D-dimer, pro-thrombotic factors, and physical activity levels in patients with peripheral arterial disease. Vasc Med (2004) 0.89
Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. Thromb Res (2011) 0.88
Unique biochemical and behavioral alterations in Drosophila shibire(ts1) mutants imply a conformational state affecting dynamin subcellular distribution and synaptic vesicle cycling. J Neurobiol (2002) 0.87
Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AalphaIVS4 + 1G>T mutation and an AalphaGln328 truncation (fibrinogen Keokuk). Blood (2003) 0.86
Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography. BJU Int (2007) 0.86
13-year long-term associations between changes in traditional cardiovascular risk factors and changes in fibrinogen levels: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Atherosclerosis (2012) 0.86
Progenitor cell release plus exercise to improve functional performance in peripheral artery disease: the PROPEL Study. Contemp Clin Trials (2013) 0.85
The impact of the congestion charging scheme on air quality in London. Part 2. Analysis of the oxidative potential of particulate matter. Res Rep Health Eff Inst (2011) 0.85
VTE prophylaxis in aesthetic surgery patients. Aesthet Surg J (2009) 0.85
Cerebral monitoring in patients undergoing carotid endarterectomy using a triple assessment technique. Interact Cardiovasc Thorac Surg (2010) 0.85
Vancomycin disulfide derivatives as antibacterial agents. Bioorg Med Chem Lett (2004) 0.85